A partir de tradutores profissionais, empresas, páginas da web e repositórios de traduções disponíveis gratuitamente
no case of osteosarcoma has been reported in clinical studies with xofigo.
xofigo klīniskajos pētījumos netika ziņots par osteosarkomas gadījumiem.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
in particular, the risk for osteosarcoma, myelodysplastic syndrome and leukaemias may be increased.
Īpaši var palielināties osteosarkomas, mielodisplastiskā sindroma un leikozes risks.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
mepact treatment should be started and supervised by a specialised doctor who has experience in diagnosing and treating osteosarcoma.
Ārstēšana ar mepact jāsāk un jāuzrauga ārstam, kam ir pieredze osteosarkomas diagnosticēšanā un ārstēšanā.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
some studies have shown a slight increase in the development of osteosarcoma among dogs that have experienced a blunt bone injury.
daži pētījumi liecina par nelielu pieaugumu attīstībā osteosarkomas starp suņiem, kas ir piedzīvojuši neass kaulu traumas.
Última atualização: 2018-02-13
Frequência de uso: 1
Qualidade:
an osteosarcoma patient in a phase ii study who had high creatinine level at enrolment showed an increase in blood urea and blood creatinine which was associated with mifamurtide use.
ii fāzes pētījumā osteosarkomas pacientam ar augstu kreatinīna līmeni pētījuma uzsākšanas laikā konstatēja urea un plazmas kreatinīna līmeņa asinīs paaugstināšanos , kas bija saistīta ar mifamurtīda lietošanu.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
none of the patients treated in the osteosarcoma studies were 65 years or older and in the phase iii randomised study, only patients up to the age of 30 years were included.
osteosarkomas pētījumos neviens no pacientiem nebija 65 gadus vecs vai vecāks, un iii fāzes randomizētā pētījumā tika iekļauti tikai pacienti vecumā līdz 30 gadiem.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
mepact has been studied in one main study involving 678 patients aged between one and 31 years with high-grade non-metastatic osteosarcoma.
mepact pētīja vienā pamatpētījumā, iesaistot 678 pacientus vecumā no viena līdz 31 gadam ar augstas malignitātes pakāpes osteosarkomu bez metastāzēm.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
rats treated with near-life time daily injections had dose-dependent exaggerated bone formation and increased incidence of osteosarcoma most probably due to an epigenetic mechanism.
gandrīz visu mūžu ar ikdienas injekcijām ārstētām žurkām bija pārmērīga kaulu veidošanās un palielināta osteosarkomas sastopamība, visticamāk – epiģenētiskā mehānisma dēļ.
Última atualização: 2017-04-26
Frequência de uso: 3
Qualidade:
mepact is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection.
mepact indicēts bērniem, pusaudžiem un jauniešiem augstas malignitātes pakāpes rezecējamu nemetastātiskas osteosarkomas ārstēšanai pēc makroskopiski pilnīgas ķirurģiskas rezekcijas.
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
mepact is used to treat osteosarcoma (bone cancer) in children, adolescents and young adults (between 2 and 30 years).
mepact lieto osteosarkomas (kaulu ļaundabīgā audzēja) ārstēšanai bērniem, pusaudžiem un gados jauniem pieaugušajiem pacientiem (no 2 līdz 30 gadu vecumam).
Última atualização: 2017-04-26
Frequência de uso: 1
Qualidade:
rats treated with near life-time daily injections had dose-dependent exaggerated bone formation and an increased incidence of bone tumours, including osteosarcoma, most probably due to an epigenetic mechanism.
Žurkām, kuras gandrīz visu dzīvi ārstēja, katru dienu veicot injekcijas, konstatēja no devas atkarīgu kaulaudu veidošanās pieaugumu un lielāku kaulu audzēju, tostarp osteosarkomas, sastopamību, ar vislielāko varbūtību epiģenētiska mehānisma dēļ.
Última atualização: 2017-04-26
Frequência de uso: 3
Qualidade:
unless otherwise specified, the following safety profile of yondelis is based on the evaluation in clinical trials of 569 patients treated up to april 2007 with the recommended treatment regime in several cancer types including soft tissue sarcoma, breast cancer, osteosarcoma, ovarian cancer, gist, melanoma and renal carcinoma.
ja vien nav norādīts savādāk, turpmāk izklāstītais yondelis drošības profils izriet no klīniskajos pētījumos iegūtajiem datiem, kas iegūti apsekojot 569 līdz 2007. gada aprīlim ārstētus pacientus, kuri ieteikto ārstēšanas shēmu saņēma, lai ārstētu dažāda veida audzējus, tai skaitā mīksto audu sarkomu, krūšu vēzi, osteosarkomu, olnīcu vēzi, kuņģa- zarnu trakta stromas šūnu vēzi, melanomu un nieru karcinomu.
Última atualização: 2012-04-10
Frequência de uso: 4
Qualidade: